2017 American Transplant Congress
Risk Factors and Consequences of De Novo Anti-HLA Donor Specific Antibodies in Kidney Transplant Recipients: The Force Awakens.
Background: Presence of anti-HLA donor specific antibodies (DSAs) has been associated with inferior kidney transplant outcomes. Identification of risk factors for de novo DSAs could…2017 American Transplant Congress
Low Level Early Onset De Novo DSA's May Not Portend Early Graft Dysfunction in Kidney Transplant Recipients.
Nephrology and Hypertension, Stony Brook Medicine, Stony Brook, NY
Background: The occurrence of anti-HLA de novo DSA (dnDSA) has been associated with the histological features of antibody-mediated rejection (ABMR) on kidney biopsy. The significance…2017 American Transplant Congress
Positive Flow Crossmatch After Negative Virtual Crossmatch -A Single Center Experience.
Pathology and Lab Medicine, London Health Sciences Center, London, ON, Canada
Aims: To determine causes of Flow Cytometry crossmatch (FCXM) after a negative virtual crossmatch (VirXM), even with sensitive solid-phase antibody assay and complete HLA typings…2017 American Transplant Congress
Characterization of Human Plasma Cell Proteasome Adaptations to Proteasome Inhibitor Therapy: A Precision Medicine Approach to Overcome Drug Resistance in Desensitization.
1U of Cincinnati, Cincinnati, OH; 2Cincinnati Children's, Cincinnati, OH
Purpose: Bone marrow niche-resident plasma cells (BMNRPCs) exhibit variable sensitivity to proteasome inhibitor (PI) therapy. Here, we characterized alterations in the gene and protein expression…2017 American Transplant Congress
Complement Binding Activity (C3d, C1q) of De Novo Donor-Specific HLA Antibody Is Associated with Increased Risk of Antibody-Mediated Rejection in Non-Sensitized Kidney Transplant Recipients.
Despite advances in therapeutic strategies and medicine, antibody mediated rejection (AMR) is a leading cause of kidney graft loss. The complement binding activity of donor-specific…2017 American Transplant Congress
Microvascular Inflammation at 4 Months Posttransplant Is Associated with Transplant Glomerulopathy at One and Two Years Independent of Rejection and Donor Specific Antibodies.
Aim: Study factors that are associated with transplant glomerulopathy (TG) in flowcytometric crossmatch negative kidney transplant recipients with no desensitization.Methods:Single center retrospective analysis of characteristics…2017 American Transplant Congress
Prediction of Positive Cytotoxic and Flow Crossmatches for Sensitized Wait List Candidates: Comparison of Luminex MFI, C1q and FcR Binding Assays.
Surgery, University of Cincinnati, Cincinnati
Clinical relevance of HLA antibodies identified in solid phase assays includes their ability to generate a positive crossmatch (XM) test, which often precludes transplantation. The…2017 American Transplant Congress
Experience with the Bacterial Enzyme IdeS (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized (HS) Kidney Allograft Recipients.
Donor specific antibodies (DSA) create an impenetrable immunologic barrier to transplantation. Current rx aimed at modification of DSAs are not effective in the most HS…2017 American Transplant Congress
Circulating Donor-Specific Memory B Cells (mBc) Discriminates Kidney Transplant Patients with Histological Lesions of ABMR in Absence of Circulating DSA.
Chronic (c)ABMR is a main cause of immune-mediated kidney allograft loss. For its diagnosis, specific histological lesions together with presence of circulating donor-specific alloantibodies (DSA)…2017 American Transplant Congress
Outcome of Systemic Monitoring of DSA and Protocol Management to Optimize Renal Allograft Outcome in a Single Transplant Center.
Denovo (dn) donor specific antibody (DSA) development has been shown to adversely affect long-term allograft survival. To improve graft outcome for kidney (K) transplant (Tx)…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 47
- Next Page »